Siegfried, a global CDMO for the pharmaceutical industry, has confirmed that all conditions have been met to close its previously announced acquisition of three drug substances sites in the US and Australia from an affiliate of SK Capital Partners. The deal will officially close on May 1, 2026.
The acquisition brings three established small-molecule drug substance facilities into Siegfried’s global network: Noramco, a large commercial manufacturing site in Wilmington, Delaware; Purisys, a clinical API development and manufacturing facility in Athens, Georgia; and Extractas Bioscience, a purified products manufacturer in Westbury, Tasmania.
Together, the sites employ around 400 people and will be fully integrated into Siegfried upon closing.
The move significantly strengthens Siegfried’s footprint in drug substances, particularly in the US, where the company plans to expand its fast-growing exclusive synthesis business by optimizing controlled substance capacity across Wilmington and its nearby Pennsville facility.
The addition of early-phase development capabilities in Athens and extraction expertise in Tasmania enhances Siegfried’s end-to-end offering from early development through to commercial production.
Marcel Imwinkelried, CEO Siegfried: “Reaching this milestone represents another important step in the execution of our EVOLVE+ strategy. The additional US manufacturing capacity and complementary capabilities strengthen our position in small-molecule drug substances and support our ambition to deliver sustainable, profitable growth.
"We look forward to welcoming our new colleagues to Siegfried and to working together to further strengthen our global network and realize its full potential."
Siegfried also issued updated 2026 guidance, with the acquisition expected to contribute approximately USD 100 million in net sales (annualized around USD 155 million), at an EBITDA margin at or above the group average.
The company now forecasts high-single-digit net sales growth in local currencies for its Drug Substance cluster, up from a previous low-single-digit outlook. Drug Products growth expectations remain unchanged at high-single-digit, bringing overall group growth to a revised high-single-digit range.
The company reaffirmed its target of a core EBITDA margin above 23%, while maintaining a positive mid-term outlook for continued profitable growth.
